Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label safety of tegaserod in female patients with dyspepsia
2004-002612-28Phase 3Completed
- Sponsor
- Novartis
- Start
- Feb 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of tegaserod in dyspepsia, sponsored by Novartis. Primary endpoints: Long-term safety at 6 months and Long-term safety at 1 year. Started Feb 2005; status: completed.
02
Drugs
tegaserod
03
Conditions
dyspepsia
Beyond the preview
Go deeper on 2004-002612-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-002612-28.